An investor who sued Verve Therapeutics Inc. for allegedly misleading investors about a clinical trial for its cholesterol medicine has voluntarily dismissed the proposed class action.
The dismissal doesn’t preclude Thomas Oldroyd from re-filing the claims, according to a notice submitted to Judge Angel Kelley of the US District Court for the District of Massachusetts on Tuesday. No reason was given for the dismissal, and attorneys for Oldroyd declined to comment.
- Oldroyd alleged that Verve overstated the potential of a drug delivery system and emphasized successful interim data without fully disclosing the circumstances under which the clinical trial would be ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.